Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Vivace advances phase I trial of VT-3989 in solid tumors

May 6, 2021

Preclinical characterization of novel small molecule inhibitor of CD38, RBN-013209

May 5, 2021

FDA clears IND for phase I/II study of Clarity's prostate cancer theranostic products

May 5, 2021

Positive topline data from GENESIS phase III study of motixafortide plus G-CSF in multiple myeloma

May 5, 2021

Cellectar Biosciences describes new phospholipid-drug conjugates for cancer

May 5, 2021

Incyte discloses new CDK2/cyclin E inhibitors

May 5, 2021

Zenshine compounds targeting E-NPP 1 have antitumor activity

May 5, 2021

Aprea begins enrollment in first-in-human study of APR-548 for TP53-mutated MDS

May 5, 2021

PXS-5505 to enter preclinical evaluation for glioblastoma

May 4, 2021

New IDH1 inhibitors presented by Shanghai Meton Pharmaceutical

May 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...